Besides, AIM-2 co-immunization has been reported to ameliorate symptoms of CVB3-induced VMC via multiple mechanisms, such as promoting specific multifunctional CD8 T cell induction, facilitating protective secretory immunoglobulin A (SIgA) response and increasing prophylactic efficacy of chitosan-DNA vaccine (Chai et al., 2014; Chai et al., 2015), all of which seemingly showed the potential of AIM2 in preventing VMC. The gene discussed is AIM2; the disease is liver mesenchymal hamartoma.